First reported 20 hours ago -
Updated 20 hours ago -
Patients with HER2 positive breast cancer derive less benefit from anti-HER2 drugs when they have PIK3CA mutations, according to Dr Evandro de Azambuja, medical director of the Br.E.A.S.T. Data Centre, Jules Bordet
Institute in Brussels, Belgium.De.. ...
[Published BioPortfolio - 20 hours ago]